Home>>Signaling Pathways>> Apoptosis>> Bcl-2 Family>>MSN-50

MSN-50

Catalog No.GC63083

MSN-50 is a Bax and Bak oligomerization inhibitor.

Products are for research use only. Not for human use. We do not sell to patients.

MSN-50 Chemical Structure

Cas No.: 1592908-75-2

Size Price Stock Qty
5 mg
$882.00
In stock
10 mg
$1,395.00
In stock
25 mg
$2,745.00
In stock
50 mg
$4,392.00
In stock
100 mg
$7,020.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

MSN-50 is a Bax and Bak oligomerization inhibitor. MSN-50 efficiently inhibits liposome permeabilization, prevents genotoxic cell death and promotes neuroprotection[1][2].

MSN-50 (0~10 uM) inhibits dye release from liposomes in a concentration-dependent fashion. MSN-50 (0~40 uM) inhibits tBid/Bax-mediated MOMP (mitochondrial outer membrane permeabilization) in a concentration-dependent manner and shows concentration-dependent inhibition of Bak-mediated MOMP. MSN-50 inhibits both Bax and Bak after activation by either cBid or Bim. MSN-50 (5 μM; BMK cells) inhibits apoptosis induced by actinomycin D and staurosporin (STS)[1][2].

[1]. Niu X, et al. A Small-Molecule Inhibitor of Bax and Bak Oligomerization Prevents Genotoxic Cell Death and Promotes Neuroprotection. Cell Chem Biol. 2017;24(4):493-506.e5.
[2]. Jensen K, et al. Pharmacological inhibition of Bax-induced cell death: Bax-inhibiting peptides and small compounds inhibiting Bax. Exp Biol Med (Maywood). 2019;244(8):621-629.

Reviews

Review for MSN-50

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MSN-50

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.